Andy Chen
Stock Analyst at Wolfe Research
(4.61)
# 377
Out of 4,479 analysts
19
Total ratings
58.33%
Success rate
50.1%
Average return
Main Sectors:
Top Industries:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKRO Akero Therapeutics | Initiates: Outperform | n/a | $22.38 | - | 1 | Jun 11, 2024 | |
| MDGL Madrigal Pharmaceuticals | Initiates: Outperform | n/a | $271.67 | - | 1 | Jun 11, 2024 | |
| VRDN Viridian Therapeutics | Initiates: Outperform | n/a | $12.16 | - | 1 | Jun 11, 2024 | |
| CLDX Celldex Therapeutics | Initiates: Outperform | n/a | $37.01 | - | 1 | Jun 11, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Peer Perform | n/a | $2.79 | - | 3 | May 14, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | n/a | $45.14 | - | 1 | Apr 10, 2024 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | n/a | $40.15 | - | 1 | Feb 15, 2024 | |
| CRSP CRISPR Therapeutics AG | Initiates: Peer Perform | n/a | $53.12 | - | 1 | Feb 15, 2024 | |
| ALNY Alnylam Pharmaceuticals | Initiates: Peer Perform | n/a | $247.61 | - | 1 | Feb 15, 2024 | |
| KYMR Kymera Therapeutics | Initiates: Peer Perform | n/a | $30.22 | - | 1 | Feb 15, 2024 | |
| ROIV Roivant Sciences | Initiates: Outperform | $17 | $10.56 | +60.98% | 1 | Feb 15, 2024 | |
| IMVT Immunovant | Initiates: Outperform | $55 | $26.52 | +107.39% | 1 | Feb 15, 2024 | |
| NTLA Intellia Therapeutics | Initiates: Peer Perform | n/a | $22.15 | - | 1 | Feb 15, 2024 | |
| VRTX Vertex Pharmaceuticals | Initiates: Outperform | n/a | $473.78 | - | 1 | Feb 15, 2024 | |
| ARGX argenx SE | Initiates: Peer Perform | n/a | $435.49 | - | 1 | Feb 15, 2024 | |
| INSM Insmed | Initiates: Outperform | $42 | $64.50 | -34.88% | 1 | Feb 15, 2024 | |
| AFMD Affimed | Assumes: Buy | $60 | $5.16 | +1,063.92% | 1 | Aug 8, 2023 |
Akero Therapeutics
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $22.38
Upside: -
Madrigal Pharmaceuticals
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $271.67
Upside: -
Viridian Therapeutics
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $12.16
Upside: -
Celldex Therapeutics
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $37.01
Upside: -
RAPT Therapeutics
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $2.79
Upside: -
Ionis Pharmaceuticals
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $45.14
Upside: -
MoonLake Immunotherapeutics
Feb 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $40.15
Upside: -
CRISPR Therapeutics AG
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $53.12
Upside: -
Alnylam Pharmaceuticals
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $247.61
Upside: -
Kymera Therapeutics
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $30.22
Upside: -
Roivant Sciences
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $10.56
Upside: +60.98%
Immunovant
Feb 15, 2024
Initiates: Outperform
Price Target: $55
Current: $26.52
Upside: +107.39%
Intellia Therapeutics
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $22.15
Upside: -
Vertex Pharmaceuticals
Feb 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $473.78
Upside: -
argenx SE
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $435.49
Upside: -
Insmed
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $64.50
Upside: -34.88%
Affimed
Aug 8, 2023
Assumes: Buy
Price Target: $60
Current: $5.16
Upside: +1,063.92%